The world’s leader in fighting ovarian cancer
Every 23 minutes, someone in the US is diagnosed with ovarian cancer.

That’s why OCRA is committed to fighting the disease on all fronts.
OCRA is the largest non-government funder of ovarian cancer research and has the longest track record of impact. We have invested more than $110 million to jumpstart promising research and hasten desperately needed breakthroughs. Every day, OCRA-funded researchers are finding new ways to treat, prevent and ultimately cure ovarian cancer.
We are the voice for the ovarian cancer community, working with legislators to ensure federal ovarian cancer research and education, patient safety, and access to high-quality care are protected on Capitol Hill. We also change the way future healthcare professionals recognize ovarian cancer through our Survivors Teaching Students program.
Our programs help people navigate an overwhelming diagnosis, supporting patients and their families when and where they need it most. Our Woman to Woman peer support program pairs newly diagnosed patients with survivors who provide hope and insight, and our Ovarian Cancer National Conference brings survivors together to share knowledge and build community.
Most common symptoms:

- Bloating
- Pelvic or abdominal pain
- Difficulty eating or feeling full quickly
- Frequent and/or urgent urination

If these symptoms persist for two weeks, and are new and unusual for you, see a doctor and ask about ovarian cancer.

Those with a family history of ovarian, breast, uterine, or colorectal cancer, and with BRCA1 and BRCA2 genetic mutations, may be at a higher risk. Oral contraceptives, pregnancy, and breastfeeding may reduce risk. Learn your family history and speak with your doctor about your risk factors.

If ovarian cancer is suspected, see a gynecologic oncologist.

Get support: on the phone, online, or in person:

📞 212-268-1002   🌐 ocrahope.org   📧 info@ocrahope.org
Through your generous support, we can continue funding cures, advocating for patients, and supporting survivors.